Treatment for giant cell tumor of the spine metastasizing to the lung: A report of two cases and a literature review
- Authors:
- Published online on: December 30, 2014 https://doi.org/10.3892/ol.2014.2837
- Pages: 1321-1326
Abstract
Introduction
Giant cell tumors of the bone (GCTB) are intramedullary bone tumors with benign and locally aggressive pathological and clinical characteristics (1,2). GCTBs account for 5% of primary skeletal tumors and 21% of benign bone tumors (3,4). Although categorized as a benign bone tumor, GCTBs have been reported to have recurrence rates of 8–62% (5,6) and metastatic rates of 1.5–7% (7,8). GCTBs may have a higher prevalence in females than males, as certain studies have reported a female-to-male ratio of 1.3–1.5:1.0 (9,10). The usual primary sites for GCTBs include the distal femur, proximal tibia and distal radius (11,12). Diagnostically, X-ray and computed tomography (CT) scans may show eccentric lytic lesions with cortical extension. Pain, swelling and occasional pathological fractures are the usual manifestations of GCTB (13). There have been few studies on the primary lesions of GCTs of the spine, sacrum and small bones (14), and even fewer reporting the metastasis of these lesions to the lung. The present case study reports two cases of thoracic and sacral spinal GCTB lesions with pulmonary metastasis. Written informed consent was obtained from the patients.
Case report
Case one
A 45-year-old male presented to a local hospital with pain in the left buttock that had persisted for 2 years. The pain was particularly bad when the patient was tired, however, the patient did not initially seek medical attention, as the pain was bearable. As the pain gradually worsened over the two-year period, the patient finally attended a clinic at a local hospital. Magnetic resonance imaging showed an irregularly-shaped mass, 7.5×9.1×9.3 cm in size (Fig. 1). Surgeons in the hospital carried out resection of the tumor and sacrum at the level of the 4th sacral vertebra. Immunohistochemical staining for the pre-operative fine-needle biopsy and the post-operative resection showed the lesion to be AE1/AE3(−), cluster of differentiation 68(+), p53(+) and S-100(+), with a Ki-67 of 20%. The histopathological examinations of the lesion established the diagnosis of a GCTB (Fig. 2).
At the follow-up examination four months after the first surgery, a chest CT scan revealed a nodule with clear borders in the anterior upper left lobe of the lung (Fig. 3). Subsequent to a fine-needle biopsy, the 7.5×2.5×2.5-cm pulmonary lobe, which contained the 2.0×1.0×0.6-cm mass, was resected. The fine-needle and incisional biopsies each supported the diagnosis of a GCTB that had metastasized to the lung (Fig. 4).
Nine months after the first surgery, a follow-up magnetic resonance imaging (MRI) scan showed a recurrent mass at the site of the original GCTB lesion (Fig. 5). The patient was transferred to the Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital (Beijing, China) and a surgical resection of the lesion was performed and the sacral body was excised at the level of the 3rd sacral vertebra (Fig. 6). Histopathological analysis after the surgery confirmed that it was a recurrent lesion from the original GCTB (Fig. 7).
A chest CT scan performed at a follow-up examination 21 months after the first surgery, showed numerous metastatic nodules in diffuse and random distributions in each lung (Fig. 8). The patient refused to undergo any further surgical treatment or chemotherapy. The last follow-up took place 33 months after the first surgery, during which a CT scan found no local recurrence, and the patient complained of no pain at the site of the original lesion (Fig. 9). A chest CT scan showed several newly developed nodules, the largest being 7 mm in diameter (Fig. 10). However, the patient reported no chest pain or trouble in breathing.
Case two
A 30-year-old female presented to a local hospital due to back pain that had persisted for one year. MRI revealed a 3.2×3.8×3.3-cm lesion in the twelfth thoracic vertebral body, with evident compression of the adjacent spinal canal and foramen. A 3.0×3.4×5.6-cm mass was also present in the spinal canal and posterior column of the T12 vertebra (Fig. 11). A fine-needle biopsy was performed and the tumor was diagnosed as a GCTB (Fig. 12).
The patient was transferred to the Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital and computer-guided surgery was subsequently performed to resect the primary tumor (Fig. 13). The spine was stabilized by vertical and horizontal rods fixed by eight pedicle screws fixed into the 10th and 11th thoracic vertebrae, and the 1st and 2nd lumbar vertebrae. The vertebral body of the 12th thoracic vertebra was removed and replaced by a mesh cage filled with bone cement. A titanium palate with four screws was fixed laterally on the 11th thoracic and 1st lumbar vertebrae to provide reinforcement (Fig. 14). Due to the possibility of pulmonary metastasis, a chest CT scan was ordered, which showed multiple nodules of varying sizes in each lung (Fig. 15). Subsequent to a recovery period, the patient was advised to seek further surgical resection in a more specialized hospital or receive resection of the pulmonary metastasis. The patient was subsequently lost to follow-up.
Discussion
Giant cell tumors of the bone within the vertebrae are rare, accounting for just 2.7–6.5% of all GCTB (15). According to the literature, the sacrum may be the most common site for this lesion, followed by the thoracic, cervical and lumbar segments (16). Patients with vertebral GCTB usually demonstrate clinical manifestations such as pain with radicular distribution, weakness and sensory deficits. A variety of imaging modalities, including magnetic resonance imaging, CT scans, radionuclide imaging and positron emission tomography, are useful tools for the diagnosis for the diagnosis of GCT of the spine. Fine-needle aspiration biopsy can be used to aid the differential diagnosis and confirm the final diagnosis.
The ideal treatment for GCTB consists of an en-bloc excision at the early stages of the development of the lesion (17). However, due to the complicated anatomical structure of the spine and adjuvant spinal tissues, the surgical treatment of tumors of the spine is extremely challenging. In case one of the present study, the local hospital that the patient attended did not have much experience with rare sacral GCTB, and therefore failed to obtain an en-bloc resection. This was probably the most significant cause of the recurrent lesion and lung metastases not long after the first surgical treatment. In our center, the majority of patients are treated by senior surgeons who perform GCTB resection with the assistance of computer navigation, which predominantly achieves en-bloc resection of the tumor. In case one, following the resection of the recurrent lesion in our center, there was no further recurrence at the original site of the tumor and the metastatic lesions in the lungs were relatively stable with no symptoms. In case two, although the patient was lost to follow-up after the first surgery, it is not likely that there will be further recurrence or metastasis.
Although radiotherapy is recommended in cases of unresectable GCTB (18), it is not suitable for vertebral lesions, as it may cause spinal cord myelitis and malignant transformation of the tumor (19,20). Chemotherapy is also not highly recommended for the treatment of GCTB due to its toxic effects and the normally benign nature of GCTB (21). Thus, there is no standard chemical therapy protocol for the lesion. However, denosumab, a novel drug that inhibits the function of the cytokine receptor activator of nuclear factor-κB ligand (RANKL) may be an effective alternative based on the fact that GCTs overexpress RANKL and its receptor (22). Although the two patients in the present study refused to receive chemotherapy, certain other patients with GCTB that metastasized to the lung received a chemotherapy regime consisting of Adriamycin, ifosfamide and mitoxantrone, resulting in more growth of the metastatic tumor in the lung compared with the tumors of those who did not receive chemotherapy (23). However, randomized controlled trials should be carried out to evaluate the pros and cons of chemotherapy for GCTB with pulmonary metastasis.
Acknowledgements
The present study was funded by the National Natural Science Foundation Project of China (grant no. 61372179).
References
Gong L, Liu W, Sun X, et al: Histological and clinical characteristics of malignant giant cell tumor of bone. Virchows Arch. 460:327–334. 2012. View Article : Google Scholar : PubMed/NCBI | |
Enneking WF: Musculoskeletal Tumor Surgery. Churchill Livingstone, Inc; New York (NY): 1983 | |
Kivioja AH, Blomqvist C, Hietaniemi K, et al: Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop. 79:86–93. 2008. View Article : Google Scholar : PubMed/NCBI | |
Lackman RD, Hosalkar HS, Ogilvie CM, et al: Intralesional curettage for grades II and III giant cell tumors of bone. Clin Orthop Relat Res. 438:123–127. 2005. View Article : Google Scholar : PubMed/NCBI | |
Balke M, Schremper L, Gebert C, et al: Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 134:969–978. 2008. View Article : Google Scholar : PubMed/NCBI | |
Arbeitsgemeinschaft Knochentumoren. Becker WT, Dohle J, Bernd L, Braun A, et al: Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am. 90:1060–1067. 2008. View Article : Google Scholar : PubMed/NCBI | |
Prosser GH, Baloch KG, Tillman RM, Carter SR and Grimer RJ: Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res. 211–218. 2005. View Article : Google Scholar : PubMed/NCBI | |
Vult von Steyern F, Bauer HC, Trovik C, et al: Scandinavian Sarcoma Group: Treatment of local recurrences of giant cell tumour in long bones after curettage and cementing. A Scandinavian Sarcoma Group study. J Bone Joint Surg Br. 88:531–535. 2006. View Article : Google Scholar : PubMed/NCBI | |
Harness NG and Mankin HJ: Giant-cell tumor of the distal forearm. J Hand Surg Am. 29:188–193. 2004. View Article : Google Scholar : PubMed/NCBI | |
Moon JC, Kim SR, Chung MJ and Lee YC: Multiple pulmonary metastases from giant cell tumor of a hand. Am J Med Sci. 343:171–173. 2012. View Article : Google Scholar | |
Osaka S, Sugita H, Osaka E, et al: Clinical and immunohistochemical characteristics of benign giant cell tumour of bone with pulmonary metastases: case series. J Orthop Surg (Hong Kong). 12:55–62. 2004. | |
Xiuchun Yu, Ming Xu, Songfeng Xu and Qing Su: Clinical outcomes of giant cell tumor of bone treated with bone cement filling and internal fixation, and oral bisphosphonates. Oncol Lett. 5:447–451. 2013. | |
Ropars M, Kaila R, Cannon SR and Briggs TW: Primary giant cell tumours of the digital bones of the hand. J Hand Surg Eur Vol. 32:160–164. 2007. View Article : Google Scholar : PubMed/NCBI | |
Averill RM, Smith RJ and Campbell CJ: Giant-cell tumors of the bones of the hand. J Hand Surg Am. 5:39–50. 1980. View Article : Google Scholar : PubMed/NCBI | |
Shimada Y, Hongo M, Miyakoshi N, et al: Giant cell tumor of fifth lumbar vertebrae: two case reports and review of the literature. Spine J. 7:499–505. 2007. View Article : Google Scholar : PubMed/NCBI | |
Bidwell JK, Young JW and Khalluff E: Giant cell tumor of the spine: computed tomography appearance and review of the literature. J Comput Tomogr. 11:307–311. 1987. View Article : Google Scholar : PubMed/NCBI | |
Niu X, Zhang Q, Hao L, et al: Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am. 94:461–467. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bhatia S, Miszczyk L, Roelandts M, et al: Radiotherapy for marginally resected, unresectable or recurrent giant cell tumor of the bone: a rare cancer network study. Rare Tumors. 3:e482011. View Article : Google Scholar | |
Khan DC, Malhotra S, Stevens RE, et al: Radiotherapy for the treatment of giant cell tumor of the spine: a report of six cases and review of the literature. Cancer Invest. 17:110–113. 1999. View Article : Google Scholar : PubMed/NCBI | |
Chen ZX, Gu DZ, Yu ZH, et al: Radiation therapy of giant cell tumor of bone: analysis of 35 patients. Int J Radiat Oncol Biol Phys. 12:329–334. 1986. View Article : Google Scholar : PubMed/NCBI | |
Cheng YY, Huang L, Lee KM, et al: Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int. 75:71–77. 2004. View Article : Google Scholar : PubMed/NCBI | |
Thomas D, Henshaw R, Skubitz K, et al: Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 11:275–280. 2010. View Article : Google Scholar : PubMed/NCBI | |
Klenke FM, Wenger DE, Inwards CY, Rose PS and Sim FH: Recurrent giant cell tumor of long bones: analysis of surgical management. Clin Orthop Relat Res. 469:1181–1187. 2011. View Article : Google Scholar : |